Catheter ablation does not improve quality of life related to atrial fibrillation

A recent study published in The Lancet has found that catheter ablation, a procedure used to treat atrial fibrillation, does not significantly improve patients' quality of life compared to a sham procedure. Despite reducing recurrence of atrial fibrillation, the catheter ablation did not lead to any notable improvement in patients' quality of life after six months.

This conclusion comes from the PVI-SHAM-AF trial, which involved 262 patients with symptomatic atrial fibrillation who were randomly assigned to either receive catheter ablation or a sham procedure. The sham procedure involved receiving conscious sedation for the same duration and in the same setting as the standard procedure, but no catheter was inserted.

The primary endpoint of the study was the change in AF-specific quality of life scores from baseline to six months. Both groups showed improvement in quality of life scores, but there was no significant difference between them. The study also found that freedom from atrial fibrillation was higher in the catheter ablation group (73%) compared to the sham group (52%).

However, the researchers suggest that the improvement in quality of life scores may be due to nonspecific or placebo-related effects rather than the catheter ablation itself. Factors such as a placebo effect, optimization of therapies, or other unmeasured factors might contribute to the perceived improvement in quality of life. While catheter ablation does delay the progression of atrial fibrillation, this study highlights that patients may not necessarily experience a significant improvement in their quality of life after undergoing the procedure.